Gilead pauses access to experimental Covid-19 drug due to ‘overwhelming demand’

Gilead Sciences has temporarily stopped granting patients access to remdesivir, its experimental drug against the novel coronavirus that causes Covid-19, citing “overwhelming demand,” the company said Sunday.